Compare Novartis AG (NVS) vs Silvercorp Metals Inc. Common Shares (SVM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Silvercorp Metals Inc. Common Shares — how do they compare? Novartis AG trades at $150.38 (market cap $279.90B), while Silvercorp Metals Inc. Common Shares trades at $9.47 (market cap $2.09B). The key difference: Novartis AG is far larger — about 133.9× Silvercorp Metals Inc. Common Shares's market cap, and Novartis AG pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Silvercorp Metals Inc. Common Shares for 0 Days on average.
| NVS | SVM | |
|---|---|---|
Market Cap | $279.90B | $2.09B |
Volume | 1,647,300 | 3,359,240 |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $15.71 |
52-Week Low | $121.80 | $6.09 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $321.22B | $1.82B |
Dividend Yield | 3.23% | 0.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $142.41, down 0.99% on the day, with a bearish technical signal and mixed earnings history. The company maintains strong profitability with a net income margin of 22.5% and ROE of 30.55%, though recent clinical trial setbacks and a $7.8 billion licensing deal with China's Abogen highlight strategic shifts. Cash flow from operations remains robust at $19.14 billion for 2025, supporting ongoing investments.
The outlook is cautious; analyst consensus is a 'Hold' with a $146 price target, reflecting concerns over pipeline execution despite solid fundamentals. Key risks include drug trial failures and regulatory scrutiny, while the current valuation at a P/E of 22.19 offers moderate appeal amid sector volatility.
Silvercorp Metals (SVM) trades at $10.03, down 2.62% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue grew significantly from $299M in 2025 to $495M in 2026, though net income margin compressed. Analyst consensus is 60% buy with no sell ratings. Recent news highlights expansion into Ecuador and Kyrgyzstan to diversify geographic risk and a renewed share repurchase program.
The outlook is cautiously optimistic, driven by production expansion and strong operational cash flow, but tempered by execution risks in new jurisdictions and margin pressure. Key opportunities include global growth initiatives and efficient cost structure, while risks involve geopolitical exposure and volatile metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Silvercorp Metals Inc. Common Shares
Silvercorp Metals Inc. is a Canadian mining company that operates underground silver-lead-zinc mines and processing plants in China, with additional exploration projects in Ecuador.
Read more on SVM →
